Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Ontaneda

Showing results (21-30 of 193) with videos related to

Pageof 20
Sort By:
Expert Review of Clinical Immunology|March 1, 2013
The benefits and risks of alemtuzumab in multiple sclerosisDaniel Ontaneda, Jeffrey A Cohen
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 27, 2012
EDSS improvement: recovery of function or noise?Daniel Ontaneda, Jeffrey A Cohen
Neurology|March 12, 2022
Slowly Expanding Lesions: A New Target for Progressive Multiple Sclerosis Trials?Sarah B Simmons, Daniel Ontaneda
Neurodegenerative Disease Management|September 15, 2018
Identifying a new subtype of multiple sclerosisBruce D Trapp, Daniel Ontaneda
Expert Review of Clinical Pharmacology|November 26, 2011
Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720)Daniel Ontaneda, Jeffrey A Cohen
Degenerative Neurological and Neuromuscular Disease|July 28, 2018
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapiesJenny J Feng, Daniel Ontaneda
Continuum (Minneapolis, Minn.)|August 7, 2013
Multiple sclerosis treatment: risk mitigationDaniel Ontaneda, Robert J Fox
The International Journal of Neuroscience|October 12, 2013
Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?Daniel Ontaneda, Robert J Fox
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2016
Imaging as an Outcome Measure in Multiple SclerosisDaniel Ontaneda, Robert J Fox
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 4, 2017
The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical TrialsKedar R Mahajan, Daniel Ontaneda
Pageof 20

Showing results (21-30 of 193) with videos related to

Sort By:
Pageof 20
Expert Review of Clinical Immunology|March 1, 2013
The benefits and risks of alemtuzumab in multiple sclerosisDaniel Ontaneda, Jeffrey A Cohen
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 27, 2012
EDSS improvement: recovery of function or noise?Daniel Ontaneda, Jeffrey A Cohen
Neurology|March 12, 2022
Slowly Expanding Lesions: A New Target for Progressive Multiple Sclerosis Trials?Sarah B Simmons, Daniel Ontaneda
Neurodegenerative Disease Management|September 15, 2018
Identifying a new subtype of multiple sclerosisBruce D Trapp, Daniel Ontaneda
Expert Review of Clinical Pharmacology|November 26, 2011
Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720)Daniel Ontaneda, Jeffrey A Cohen
Degenerative Neurological and Neuromuscular Disease|July 28, 2018
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapiesJenny J Feng, Daniel Ontaneda
Continuum (Minneapolis, Minn.)|August 7, 2013
Multiple sclerosis treatment: risk mitigationDaniel Ontaneda, Robert J Fox
The International Journal of Neuroscience|October 12, 2013
Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?Daniel Ontaneda, Robert J Fox
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2016
Imaging as an Outcome Measure in Multiple SclerosisDaniel Ontaneda, Robert J Fox
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 4, 2017
The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical TrialsKedar R Mahajan, Daniel Ontaneda
Pageof 20